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INTRODUCTION: Imipenem-resistant Pseudomonas aeruginosa resulting from metallo-b-lactamases has been
reported to be an important cause of nosocomial infection and is a critical therapeutic problem worldwide,
especially in the case of bacteremia.
OBJECTIVES: To determine the frequency of metallo-b-lactamases among imipenem-resistant Pseudomonas
aeruginosa isolates and to compare methods of phenotypic and molecular detection.
METHODS: During 2006, 69 imipenem-resistant Pseudomonas aeruginosa samples were isolated from blood and
tested for metallo-b-lactamase production using phenotypic methods. Minimal Inhibitory Concentratrions (MIC)
(mg/mL) was determined with commercial microdilution panels. Pulsed Field Gel Electrophoresis (PFGE) was
performed among metallo-b-lactamase producers.
RESULTS: Of all the blood isolates, 34.5% were found to be imipenem-resistant Pseudomonas aeruginosa. Positive
phenotypic tests for metallo-b-lactamases ranged from 28%-77%, and Polymerase Chain Reaction (PCR) were
positive in 30% (of note, 81% of those samples were blaSPM-1 and 19% were blaVIM-2). Ethylenediamine tetracetic
acid (EDTA) combinations for the detected enzymes had low kappa values; thus, care should be taken when use it as
a phenotypic indicator of MBL. Despite a very resistant antibiogram, four isolates demonstrated the worrisome
finding of a colistin MIC in the resistant range. PFGE showed a clonal pattern.
CONCLUSION: Metallo-b-lactamases among imipenem-resistant Pseudomonas aeruginosa were detected in 30.4%
of imipenem-resistant Pseudomonas aeruginosa isolates. This number might have been higher if other genes were
included. SPM-1 was the predominant enzyme found. Phenotypic tests with low kappa values could be misleading
when testing for metallo-b-lactamases. Polymerase Chain Reaction detection remains the gold standard.
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INTRODUCTION
Among the b-lactams, carbapenems are potent agents for
serious treatment of gram-negative bacterial infections.
These antibiotics are well-suited to this use because of their
broad spectrum activity and resistance to hydrolysis by
most b-lactamases, including the extended-spectrum b-
lactamases (ESBL).1 These properties have led to an increase
in the use of carbapenems, especially in hospitals in which
ESBLs are highly prevalent, including many hospitals in
Brazil.2 Metallo-b-lactamase (MBL) production is increas-
ingly reported as a cause of high-level carbapenem
resistance among Pseudomonas aeruginosa (PA), an important
nosocomial pathogen that is notorious for multi-drug
resistance.3,4
MBL, an Ambler class B enzyme, is characterized by its
ability to hydrolyze carbapenems, its resistance to all
commercially available b-lactamase inhibitors and its
inhibition by metal ion chelators. The substrate spectrum
of this enzyme is quite broad, as it can hydrolyze penicillins,
cephalosporins and carbapenems, but it lacks the ability to
hydrolyze aztreonam.5
Chromosomal MBL was first detected in environmental
and opportunistic pathogenic bacteria such as Bacillus
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cereus, Aeromonas spp., and Stenotrophomonas maltophilia.
Lately, there has been a dramatic increase in the detection
and spread of acquired and transferable families of these
metallo-enzymes (IMP, VIM, SPM, GIM, SIM and AIM
enzymes).5 Brazilian surveillance studies among PA MBL
producers show SPM-1 as the most prevalent enzyme.4
Prior to the present study, we did not have information on
enzyme prevalence in our institution.
MBL standardization tests using routine phenotypic
detection are still controversial. This study aimed to deter-
mine the MBL frequency among IRPA isolates in our institu-
tion and to compare phenotypic and molecular methods of
detection.
METHODS
This study was carried out at the Hospital das Clı´nicas da
Universidade de Sa˜o Paulo, a 2500-bed university hospital
located in Sa˜o Paulo, Brazil. All patients for whom blood
culture (BACTEC 9240H - Becton DickinsonH, USA) results
were positive for IRPA in 2006 were eligible for inclusion
in the study. Each patient was included only once.
Antimicrobial Susceptibility Testing (AST) was performed
by the disk diffusion method, following Clinical and
Laboratory Standards Institute (CLSI) recommendations.6,7
All IRPAs were stored at -70 C˚ in TSB glycerol. MIC was
determined with Microscan Neg Combo Panel Type 32
(Dade BehringH, USA), and the following drugs were
analyzed: aztreonam, ceftazidime, cefepime, amikacin,
gentamicin, tobramycin, imipenem, meropenem, ciproflox-
acin, piperacilin, piperacilin/tazobactam and ticarcilin/
clavulanic acid. MICs were read manually according to
CLSI recommendations.8 Colistin MICs (mg/mL) were
determined by EtestH (AB BiodiskH, USA) and were also
interpreted according to CLSI recommendations.9 Agar
dilution was performed in the case of MIC $ 2 mg/mL.
Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC
25922 and Enterococcus faecalis ATCC 29212 were used as
quality controls, again according to CLSI recommendations.6
MBL phenotypic tests
Phenotypic tests for MBL were performed using three
methods:
1. Double Disk Synergy (DDS) was performed according
to Arakawa et al.10 with slight modifications taken from
Mendes et al.11 The inoculum was adjusted to a 0.5
McFarland standard, and a 150-mm Mueller-Hinton
(MH) agar plate (OXOIDH, USA) was inoculated. Three
blank filter paper disks were treated with 3 mL of
mercaptoacetic acid (MAA), 3 mL of 2-mercaptopropio-
nic acid (MPA) (both using an undiluted solution), and
5 mL of EDTA (100 mM) and placed on the center of the
MH plate. Imipenem (10 mg) and ceftazidime (10 mg)
disks (OXOIDH, USA) were placed 20 mm away from
the MPA and MAA disks and 10 mm away from the
EDTA disk (measured center-to-center). After overnight
incubation at 35 C˚, any synergistic inhibition zone was
interpreted to be positive by the MBL screening test.
2. EtestH MBL commercial strips (AB BiodiskH, USA) with
a wide range of imipenem concentrations (MICs: 4–
256 mg/ml) were overlaid with a constant EDTA
concentration (MICs: 1-64 mg/ml). The EtestH strips
were placed onto 150-mm MH plates that had pre-
viously been inoculated and incubated at 35 C˚ over-
night. The test was considered MBL positive when the
MIC ratio of imipenem/imipenem plus EDTA was $ 8.
The presence of a phantom zone or a deformation of
the imipenem ellipse was also considered a positive
result.12
3. The Modified Hodge Test (MHT) was performed as
described by Lee et al.13 The surface of a 150-mm MH
agar plate (OXOIDH, USA) was inoculated overnight
with a suspension of Escherichia coli ATCC 25922,
adjusted to a 0.5 McFarland standard. After a brief
drying period, a 10-mg imipenem disk (OXOIDH, USA)
was placed at the center of the plate, and the PA test
isolate was streaked heavily from the edge of the disk
toward the edge of the plate. The MHT was considered
positive if E. coli growth was observed within the
inhibition zone of the imipenem disk, giving a distorted
zone and interpreted as carbapenemase production;
For all three methods above, SPM-1-producing Pseudo-
monas aeruginosa (48-1997A) and IMP-1-producing Klebsiella
pneumoniae (Kp-Br1) strains were used as positive controls,
and Pseudomonas aeruginosa ATCC 27853 was used as the
negative control. All MBL phenotypic methods were
assessed twice by different raters.
MBL molecular detection
Polymerase Chain Reaction (PCR) analysis was per-
formed for blaSPM-1, blaIMP-1, blaIMP-2, blaVIM-1 and blaVIM-2.
The primers used were:
blaSPM-1 (forward: 59 CCTACAATCTAACGGCGACC 39,
reverse: 59 TCGCCGTGTCCAGGTATAAC 39),
blaIMP-1 (forward: 59 TGAGCAAGTTATCTGTATTC 39,
reverse: 59 TTAGTTGCTTGGTTTTGATG 39),
blaIMP-2 (forward: 59 GGCAGTCGCCCTAAAACAAA 39,
reverse: 59 TAGTTACTTGGCTGTGATGG 39),
blaVIM-1 (forward: 59 TTATGGAGCAGCAACCGATGT 39,
reverse: 59 CAAAAGTCCCGCTCCAACGA 39)
blaVIM-2 (forward: 59 AAAGTTATGCCGCACTCACC 39,
reverse: 59 TGCAACTTCATGTTATGCCG 39) as described
previously.14,15
First, the bacterial cells were boiled to lyse the cell wall and
extract the DNA, then PCR was performed. The cycling
parameters for the blaSPM-1 gene were: 95 C˚ for 5 min,
followed by 30 cycles of denaturation at 95 C˚ for 1 min,
annealing at 40 C˚ for 1 min, extension at 68 C˚ for 1 min and a
final extension at 68 C˚ for 5 min.16 The parameters used for
the blaIMP-1, blaIMP-2, blaVIM-1 and blaVIM-2 genes were: 94 C˚
for 3 min, followed by 35 cycles of denaturation at 94 C˚ for
1 min, annealing at 55 C˚ for 1 min, extension at 72 C˚ for 2 min
and a final extension at 72 C˚ for 7 min.14 The PCR products
were loaded into a 2.0% agarose gel, stained with 1%
ethidium bromide, electrophoresed and visualized under
UV light. Positive controls were the MBL-producing strains
SPM-1 (Pseudomonas aeruginosa 48-1997-A), IMP-1 (Klebsiella
pneumoniae Kp-Br1), IMP-2 (Acinetobacter baumannii AC-54/
97), VIM-1 (Pseudomonas aeruginosa VR-143/97) and VIM-2
(Pseudomonas aeruginosa 98/10/U1315). Pseudomonas aerugi-
nosa ATCC 27853 was the negative control.
The performance of the MBL phenotypic tests was
evaluated using PCR as the gold standard. The sensitivity,
specificity and positive and negative predictive values of the
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phenotypic methods were calculated according to Ilstrup.17
The kappa value was calculated in order to measure the
level of agreement between methods.18
Pulsed Field Gel Electrophoresis (PFGE)
MBL-positive isolates were genotyped using DNA macro-
restriction followed by pulsed-field gel electrophoresis
(PFGE) as described by Kaufmann.19 In brief, a bacterial
cell suspension was made in 100 mM Tris - 100 mM EDTA
buffer. An agarose gel block was prepared from 250 mL of
this suspension and 250 mL of 2% LPM agarose and was
then placed in lysis buffer (0.4 M EDTA – pH 9.4, sarcosil
1%, 100 mL proteinase K) and incubated overnight at 50 C˚.
The plugs were washed five times in CHEF-TE buffer (0.1 M
Tris, pH 7.5, 0.1 M EDTA). The DNA was digested with SpeI
(New England BioLabsH, EUA) at 37 C˚ for 12 to 20 hours
and run on a 1% agarose gel with CHEF-DRII (BioRadH,
EUA) at 14 C˚ and 6 V/cm, with pulse times of 5 and 90
seconds for 24 hours. The gels were visualized with
ethidium bromide, and the results were visually analyzed
according to the criteria of Tenover et al.20
RESULTS
In the study period, 238 PA blood isolates were analyzed,
and 82 (34.5%) were found to be resistant to imipenem
(IRPA). Thirteen IRPA isolates were excluded due to loss of
viability; thus, 69 IRPA samples were included in the study.
MIC (mg/mL) determinations confirmed the 100% imipe-
nem resistance that was initially suggested by disk diffu-
sion.
DDS results were positive in at least one of the inhibitor-
substrate combinations among 53 strains (76.8%). Individual
combinations of substrate and inhibitor showed distinct
positivity, as can be seen in Table 1, with variable
performance among the different combinations. The MBL
EtestH was positive in 53 isolates (76.8%), and the MHT was
positive in 19 isolates (27.5%).
PCR detection of MBL was positive in 21 strains (30.4%),
17 (81%) of which were positive for blaSPM-1 and 4 (19%) of
which were positive for blaVIM-2. The other genes (blaIMP-1,
blaIMP-2, blaVIM-1) were not detected.
Table 2 summarizes the sensitivity, specificity, PPV, NPV
and kappa values of the phenotypic tests for the blaSPM-1 and
blaVIM-2 genes according to the PCR results of the present
study.
MBL-producing strains detected by PCR showed 100%
resistance to ceftazidime, cefepime, gentamycin, tobramy-
cin, ciprofloxacin and meropenem. Colistin appeared to be
the most active antimicrobial agent, with MIC90 being 2 mg/
mL (only two isolates had MICs of 4 and 6 mg/mL). This
result was confirmed by agar dilution. Antibiogram and
MIC90 off all IRPA and its analysis according to MBL PCR
detection were summarized in Table 3. The PFGE patterns
of the SPM-1 and VIM-2 isolates were distinct. Among 17
SPM-1 isolates, 5 were indistinguishable, 11 were closely
related, and 1 was possibly related. Among 4 VIM-2 isolates,
2 were indistinguishable, 1 was closely related, and 1 was
different.
DISCUSSION
Imipenem-resistant Pseudomonas aeruginosa (IRPA) is a
current and significant concern, especially because of the
limited therapeutic options for this pathogen. MBL enzymes
Table 1 - Positivity of inhibitor-substrate combinations on
DDS used for detecting MBL among 69 IRPA isolates.
Combinations N˚ of positive strains %
IMP / MAA 19/53 35.8%
IMP / MPA 7/53 13.2%
IMP / EDTA 52/53 98.1%
CAZ / MAA 27/53 50.9%
CAZ / MPA 23/53 43.4%
CAZ / EDTA 47/53 88.7%
IMP: imipenem; CAZ: ceftazidime; EDTA: etilenodiaminotetracetic acid;
MAA: mercaptoacetic acid; MPA: 2-mercaptopropionic acid.
Table 2 – Performance of phenotypic methods for detecting SPM-1 and VIM-2 enzymes.
PCR (gold standard)
Phenotypic Method Genes Sensitivity (%) Specificity (%) PPV (%) NPV (%) Kappa
IMP-EDTA blaSPM-1 100 32.7 32.7 100 0.19
blaVIM-2 100 26.2 7.7 100 0.03
IMP-MAA blaSPM-1 100 96.2 89.5 100 0.92
blaVIM-2 25 72 5.3 94 -0.009
IMP-MPA blaSPM-1 35.3 98.1 85.7 82.3 0.42
blaVIM-2 25 90.7 14.3 95.2 0.12
CAZ-EDTA blaSPM-1 94.1 40.4 34 95.5 0.22
blaVIM-2 100 33.8 8.5 100 0.05
CAZ-MAA blaSPM-1 100 80.8 62.9 100 0.67
blaVIM-2 100 64.6 14.8 100 0.17
CAZ-MPA blaSPM-1 70.6 78.7 52.2 89.1 0.44
blaVIM-2 100 70.8 17.4 100 0.22
E-test MBL blaSPM-1 100 30.8 32.1 100 0.17
blaVIM-2 100 30.2 7.5 100 0.04
Hodge blaSPM-1 82.4 90.4 73.7 94 0.70
blaVIM-2 75 75.4 15.8 98 0.18
IMP: imipenem; CAZ: ceftazidime; EDTA: etilenodiaminotetracetic acid; MAA: mercaptoacetic acid; MPA: 2-mercaptopropionic acid; PPV: positive
predictive value; NPV: negative predictive value.
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may play a critical role in IRPA, given that there is a high
possibility of these carbapenemases being spread among
nosocomial isolates. The prevalence of MBLs has been
increasing significantly. MBLs now account for up to 40% of
worldwide IRPA cases; furthermore, enzyme types may
vary by regional areas.21,22 In the present study, 30.4% of the
IRPA isolates were MBL positive, with 81% positive for
SPM-1 and 19% positive for VIM-2. SPM-1 (Sa˜o Paulo
metallo-b-lactamase), initially described by Toleman et al. in
a 2002 case report from Sa˜o Paulo, is now by far the most
prevalent MBL in Brazil.16,23 Intriguingly, it is still restricted
to Brazil. VIM-2 has been identified in other Latin American
countries, such as Argentina, Chile, Colombia and
Venezuela.5,16,4,24 The blaIMP-1 gene was not detected in
our study, but it has previously been found in other
Brazilian hospitals.24,25,26 Primers for very rare MBL
enzymes that have not yet been described in our region
were not included in the present study.4,24
The prevalence of MBL-PA among other Brazilian studies
has ranged from 7.5% - 44%4,16,25,26,27 in different geo-
graphic regions. Vieira et al. reported the lowest prevalence
in the northern region.27 In 2005, Sader et al. reported a
19.7% MBL prevalence among PA isolates, and a 43.9%
IRPA prevalence, of which 55.6% were SPM-1, 30.6% were
VIM-2, and 8.3% were IMP-1.4
Phenotypic tests for MBL have not been nationally or
internationally standardized. A consensus methodology for
this routine laboratory method remains to be defined, and
questions regarding the timing and method of MBL
detection remain to be answered. Ultimately, guidelines
for the reporting of such results are needed.
DDS is a feasible option for routine laboratory testing, but
there is a need for different inhibitor combinations tests and
performance may varies among different enzymes. In our
study, MAA demonstrated the best sensitivity and specifi-
city for detecting the SPM-1 enzyme. MPA demonstrated
the best performance for detecting VIM-2. Even in the case
of the EtestH MBL strip, EDTA showed a high sensitivity but
low specificity for detecting both enzymes.
In a Brazilian study, Pica˜o et al. published very similar
results for the sensitivity and specificity of DDS phenotypic
tests, using disk-inhibitor combinations among IRPA-MBL
producing strains.28
In another recent Brazilian study, Marra et al. found a
69.6% false MBL detection rate with EDTA.26 Chu et al. also
reported that methods using EDTA are highly sensitive but
not specific, as we observed.29 These findings suggest that
caution must be taken in using only EDTA as the inhibitor
agent when analyzing MBL production, as this method may
lead to false positive results. Some authors have stated that
the EDTA concentration is critical and that this compound
may have its own bactericidal activity that leads to
expanded inhibition zones (synergy) of carbapenems that
are not associated with true MBL production. EDTA may
also act on membrane permeability, increasing susceptibility
to several antimicrobials including imipenem, which would
also lead to false interpretations of MBL synergy tests.30 As
another possibility of false MBL phenotypic detection, OXA
enzymes that act like carbapenemases may also be affected
by the EDTA inhibitory effect.31 This poor EDTA specificity
is worrisome given that EtestH MBL is a practical method for
routine testing for MBL in a standard laboratory. Tests with
low specificity may have a negative impact on the range of
therapeutic options available and could increase the costs of
nosocomial isolation precautions. False negative results of
EtestH for MBL have also been reported in isolates with an
imipenem MIC , 4 mg/mL,12 but this possibility could not
be assessed in our study because our isolates were all
imipenem resistant (MIC . 16 mg/mL).
The positive Modified Hodge Test (MHT) is a carbape-
nemase-based indicator, not a MBL-specific test. That said, it
may indicate enzyme production. In the present study, the
MHT demonstrated good sensitivity and specificity for
SPM-1 and VIM-2, reinforcing the opinions of other
authors,32 The MHT is a feasible test for flagging possible
production of MBL.
The IRPA strains studied had a multi-drug-resistant
phenotype, and colistin was the most effective antimicro-
bial. In our hospital, colistin is considered a first-line drug
for many severe nosocomial infections; thus, a selective
pressure might explain why we found four isolates with
MICs . 2 mg/mL.
Aztreonam was the second most active drug, but 14.3% of
the MBL-producing isolates were not susceptible to aztreo-
nam, suggesting a possible association with other resistance
mechanisms similar to Group A enzymes.33 Toleman et al.
Table 3 - Susceptibility profile and MIC90 of 69 IRPA samples and the analysis according to MBL production.
Overall (n = 69) MBL positive (n = 21) MBL negative (n = 48)
Antimicrobial %S %I %R MIC90(mg/mL) %S %I %R MIC90(mg/mL) %S %I %R MIC90(mg/mL)
Aztreonam 40.6 13 46.4 . 16 85.7 9.5 4.8 16 20.8 14.6 64.6 . 16
Ceftazidime 14.5 4.3 81.2 . 16 0 0 100 . 16 20.8 6.3 72.9 . 16
Cefepime 13 18.8 68.2 . 16 0 0 100 . 16 18.8 27.1 54.1 . 16
Amikacin 43.5 4.3 52.2 . 32 4.8 0 95.2 . 32 60.4 6.3 33.3 . 32
Gentamicin 34.8 8.7 56.5 . 8 0 0 100 . 8 50 12.5 37.5 . 8
Tobramycin 43.5 1.4 55.1 . 8 0 0 100 . 8 62.5 2.1 35.4 . 8
Imipenem 0 0 100 . 8 0 0 100 . 8 0 0 100 . 8
Meropenem 7.2 4.4 88.4 . 8 0 0 100 . 8 10.4 6.3 83.3 . 8
Ciprofloxacin 14.5 0 85.5 . 2 0 0 100 . 2 20.8 0 79.2 . 2
Piperacilin 47.8 0 52.2 . 64 76.2 0 23.8 . 64 35.4 0 64.6 . 64
Pip / Tazo 47.8 0 52.2 . 64 76.2 0 23.8 . 64 35.4 0 64.6 . 64
Tic / Ac. Clav. 28.9 0 71.1 . 64 33.3 0 66.7 . 64 27.1 0 72.9 . 64
Colistin (E-testH) 94.2 1.5 4.3 2 90.5 4.7 4.8 2 95.8 2.1 2.1 2
%S: sensitivity percentage; %I: intermediate percentage; %R: resistance percentage; Pip: piperacilin; Tazo: tazobactam; Tic: ticarcilin; Ac. Clav: clavulanic
acid.
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demonstrated that a large proportion of MBL genes are
associated with one or more aminoglycoside- or b-lactam-
resistant genes,34 partially explaining multi-drug-resistant
cases.
MBL-PFGE showed a clonal-predominant genotype,
reinforcing the importance of interventions to reduce
cross-infection, especially once the majority of MBL-coding
genes are in high-mobility genetic elements. The continued
spread of such pathogens would be a clinical catastrophe, as
outlined by other commentators.35
CONCLUSION
A high prevalence of MBL among Pseudomonas aeruginosa
is a critical problem representing a practical therapeutic
challenge. Even though early recognition of MBL through
routine laboratory testing is desirable, care should be taken
when phenotypic tests are interpreted based on inhibitor
synergy. In such cases, PCR should also be done to validate
such results. The best method for MBL screening should be
based on local factors such as bacterial type, MBL enzyme
prevalence and the technical abilities of relevant facilities.
REFERENCES
1. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for
b-lactamases and its correlation with molecular structure. Antimicrobial
Agents Chemother. 1995;39:1211-33.
2. Marra AR, Wey SB, Castelo A, Gales AC, Cal RG, Filho JR, et al.
Nosocomial bloodstream infections caused by Klebsiella pneumoniae:
impact of extended-spectrum beta-lactamase (ESBL) production on
clinical outcome in a hospital with high ESBL prevalence. BMC Infect
Dis. 2006;14:6-24.
3. Livermore DM. Multiple mechanisms of antimicrobial resistance in
Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;
34:634-40, doi: 10.1086/338782.
4. Sader HS, Reis AO, Silbert S, Gales AC. IMPs, VIMs and SPMs: the
diversity of metallo-b-lactamases produced by carbapenem-resistant
Pseudomonas aeruginosa in a Brazilian hospital. Clin Microbiol Infect.
2005;11:73-6, doi: 10.1111/j.1469-0691.2004.01031.x.
5. Queenan AM, Bush K. Carbapenemases: the Versatile b-lactamases. Clin
Microbiol Rev. 2007;20:440-58, doi: 10.1128/CMR.00001-07.
6. Clinical and Laboratory Standards Institute. Performance Standards for
Antimicrobial Disk Susceptibility Tests: Aprovved Standard – Eighth
Edition. CLSI document M2-A8, Wayne, PA, USA.
7. Clinical and Laboratory Standards Institute. Performance Standards for
antimicrobial susceptibility testing. CLSI document M100-S15, Wayne,
PA, USA, 2005.
8. Clinical and Laboratory Standards Institute. Performance Standards for
antimicrobial susceptibility testing. CLSI document M100-S16, Wayne,
PA, USA, 2006.
9. Clinical and Laboratory Standards Institute. Performance Standards for
antimicrobial susceptibility testing. CLSI document M100-S17, Wayne,
PA, USA, 2007.
10. Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H,
et al. Convenient test for screening metallo-b-lactamase-producing gram-
negative bacteria by using thiol compounds. J Clin Microbiol. 2000;38:
40-3.
11. Mendes RE, Castanheira M, Pignatari AC, Gales AC. Metallo-b-
lactamases. J Bras Patol Med Lab. 2006;42:103-13, doi: 10.1590/S1676-
24442006000200007.
12. Walsh TR, Bolmstorm A, Qwarnstorm A, Gales AC. Evaluation of a new
E-test for detecting metallo-b-lactamases in routine clinical testing. J Clin
Microbiol. 2002;40:2755-9, doi: 10.1128/JCM.40.8.2755-2759.2002.
13. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge
and EDTA-disk synergy tests to screen metallo-b-lactamase producing
strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect.
2001;7:88-91, doi: 10.1046/j.1469-0691.2001.00204.x.
14. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, et al. Metallo-b-
lactamases in Clinical Pseudomonas isolates in Taiwan and identification
of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents
Chemother. 2001;45:2224-8, doi: 10.1128/AAC.45.8.2224-2228.2001.
15. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR.
Molecular characterization of a b-lactamase gene, blaGIM-1, encoding a
new subclass of metallo-b-lactamase. Antimicrob Agents Chemother.
2004;48:4654-61, doi: 10.1128/AAC.48.12.4654-4661.2004.
16. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct
Brazilian regions of an epidemic carbapenem-resistant Pseudomonas
aeruginosa producing SPM metallo-b-lactamase. J Antimicrob Chemoter.
2003;52:699-702, doi: 10.1093/jac/dkg416.
17. Ilstrup DM. Statistical Methods in Microbiology. Clin Microbiol Rev.
1990;3:219-26.
18. Viera AJ, Garrett JM. Understanding interobserver agreement: The
Kappa statistic. Fam Med. 2005;37:360-3.
19. Kaufmann ME. Pulsed Field Gel Electrophoresis. In: Woodford N,
Johnson AP, editors. Molecular Bacteriology: Protocols and Clinial
Applications. 1st ed. New Jersey: Ed. Humana Press; 1998. Cap.15,
p.33-50.
20. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing
DH, Swaminathan B. Interpreting chromosomal DNA restriction
patterns produced by pulsed-field gel electrophoresis: criteria for
bacterial strain typing. J Clin Microbiol. 1995;33:2233-9.
21. Livermore DM. Interplay of impermeability and chromosomal b-
lactamase activity in imipenem-resistant Pseudomonas aeruginosa.
Antimicrob Agents Chemoter. 1992;36:2046-8.
22. Livermore DM. Pseudomonas, porins, pumps, and carbapenens.
J Antimicrob Chemoter. 2001;47:247-50, doi: 10.1093/jac/47.3.247.
23. Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones
RN, et al. Molecular characterization of SPM-1, a novel metallo-b-
lactamase isolated in Latin America: report from the SENTRY anti-
microbial surveillance programme. J Antimicrob Chemother.
2002;50:673-9, doi: 10.1093/jac/dkf210.
24. Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN.
Dissemination and diversity of metallo-b-lactamases in Latin America:
report from the SENTRY Antimicrobial Surveillance Program.
Int J Antimicrob Agents. 2005;25:57-61, doi: 10.1016/j.ijantimicag.2004.
08.013.
25. Martins AF, Zavascki AP, Gaspareto PB, Barth AL. Dissemination of
Pseudomonas aeruginosa producing SPM-1-like and IMP-1-like metallo-b-
lactamases in Hospitals from Southern Brazil. Infection. 2007;35:457-60,
doi: 10.1007/s15010-007-6289-3.
26. Marra AR, Pereira CAP, Gales AC, Menezes LC, Cal RGR, Souza JMA,
et al. Bloodstream infections with metallo-b-lactamase producing
Pseudomonas aeruginosa: Epidemiology, Microbiology, and Clinical
Outcomes. Antimicrob Agents Chemother. 2006;50:388-90, doi: 10.
1128/AAC.50.1.388-390.2006.
27. Vieira VV, Fonseca EL, Vicente AC. Metallo-b-lactamases produced by
carbapenem-resistant Pseudomonas aeruginosa in Brazil [letter] Clin
Microbiol Infect. 2005.
28. Pica˜o RC, Andrade SS, Nicoletti AG, Campana EH, Moraes GC, Mendes
RE, et al. Metallo-b-lactamase detection: Comparative evaluation of
Double-Disk Synergy versus Combined Disk Tests for IMP-, GIM-, SIM-,
SPM- or VIM-producing isolates. J Clin Microbiol. 2008;46:2028-37, doi:
10.1128/JCM.00818-07.
29. Chu YW, Cheung TK, Ngan JYW, Kam KM. EDTA susceptibility leading
to false detection of metallo-b-lactamase in Pseudomonas aeruginosa by E-
test and an imipenem–EDTA disk method. Int J Antimicrob Agents.
2005;26:340-1, doi: 10.1016/j.ijantimicag.2005.07.004.
30. Denny B, West P, Panigrahi D. Effects of permeabilizers on antimicrobial
susceptibility of Stenotrophomonas maltophilia and Acinetobacter spp.
J Microbiol Immunol Infect. 2003;36:72-6.
31. Danel F, Paetzel M, Strynadka NC. Effect of divalent metal cations on the
dimerization of OXA-10 and -14 class D b-lactamases from Pseudomonas
aeruginosa. Biochemistry. 2001;40:9412-20, doi: 10.1021/bi0025969.
32. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the hodge test
and the imipenem-EDTA double-disk synergy test for differentiating
metallo-b-lactamase producing isolates of Pseudomonas sp. and
Acinetobacter spp. J Clin Microbiol. 2003;41:4623-9, doi: 10.1128/JCM.41.
10.4623-4629.2003.
33. Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones
RN, et al. Molecular characterization of SPM-1, a novel metallo-b-
lactamase isolated in Latin America: report from the SENTRY anti-
microbial surveillance programme. J Antimicrob Chemother. 2002;50:
673-9, doi: 10.1093/jac/dkf210.
34. Toleman MA, Biedenbach D, Bennett DMC, Jones RN, Walsh TR. Italian
metallo-b-lactamases: a national problem? Report from the SENTRY
Antimicrobial Surveillance Programme. J Antimicrob Chemother.
2005;55:61-70, doi: 10.1093/jac/dkh512.
35. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-b-lactamases:
the quiet before the storm? Clin Microbiol Rev. 2005;18:306-25, doi: 10.
1128/CMR.18.2.306-325.2005.
CLINICS 2010;65(9):825-829 Metallo-b-lactamses among Pseudomonas aeruginosa
Franco MRG et al.
829
